ASX RELEASE

19 March 2018

KAZIA PRESENTION TO PROACTIVE INVESTORS: CEO SERIES

Sydney, 19 March 2018 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to provide to the market the presentation which will be given in the Proactive Investors CEO series today in Sydney and on Wednesday this week in Melbourne.

[ENDS]

About Kazia Therapeutics Limited

Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications.

Our lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme, the most common and most aggressive form of primary brain cancer. Licensed from Genentech in late 2016, GDC-0084 is due to enter a phase II clinical trial in late March / early April 2018. Initial data is expected in early calendar 2019, and the study is expected to complete in 2021.

TRX-E-002-1 (Cantrixil), is a third-generation benzopyran molecule with activity against cancer stem cells, and is being developed to treat ovarian cancer. TRX-E-002-1 is currently undergoing a phase I clinical trial in Australia and the United States. Initial data is expected in the first half of calendar 2018.

For more information, please visit www.kaziatherapeutics.com.

KAZIA THERAPEUTICS

An emerging oncology developer with two clinical-stage programs

Proactive Investors
CEO Series

Sydney & Melbourne
20 & 21 March 2018

ASX: KZA | NASDAQ : KZIA

Forward-Looking Statements

This presentation contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including changes from anticipated levels of customer acceptance of existing and new products and services and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to sales, future international, national or regional economic and competitive conditions, changes in relationships with customers, access to capital, difficulties in developing and marketing new products and services, marketing existing products and services update the forward-looking information contained in this presentation.

Investment Highlights

1. Cancer-focused biotech with two distinct therapies in clinical trials
   - GDC-0084 entering phase II trial for brain cancer
   - Cantrixil currently in phase I trial for ovarian cancer

2. Business strategy focused on owning assets at a critical stage in their value life-cycle, delivering earlier returns to shareholders

3. Experienced team, with extensive international background in big pharma and biotech

4. Publicly-listed company, traded on ASX and NASDAQ
   - Market cap ~AU$ 27 million
   - Current assets of ~AU$ 14.8 million
   - Holding in Noxopharm Limited (ASX: NOX) through IP settlement

Kazia is focused on development of high-potential novel therapies for poorly-served cancers

Identify Value

- Bring in under-valued assets from other pharmaceutical companies

Build Value

- Conduct focused clinical trials
- Identify optimal patient groups
- Understand safety and dosing
- Engage with external experts

Realise Value

- Partner with big pharma for late-stage development to bring to market



$

Proceeds of outbound licensing reinvested in earlier-stage assets

Reduce cycle time and accelerate returns: 2-4 years to get to value inflection

Improve portfolio strength: access the best global innovation

Mitigate risk: bring in assets which already partially de-risked

A strong team brings international experience in big pharma and early-stage biotech

Board

Iain Ross
Chairman

Executive and Board roles in pharma and small biotech

Bryce Carmine
Deputy Chairman

36 years executive experience in Eli Lilly

Steven Coffey
Non-Executive Director

Chartered accountant with extensive governance experience

Dr James Garner
Chief Executive Officer
& Executive Director

Physician / MBA; Extensive drug development experience

Scientific Advisory Board

Professor Sir Murray Brennan
Emeritus Chairman of Cancer Surgery at Memorial Sloan Kettering Hospital, New York

Dr Karen Ferrante
Former Chief Medical Officer at Millennium Pharmaceuticals

Professor Peter Gunning
Head of School of Medical Sciences at University of New South Wales

Professor Alex Matter
Former Global Head of Oncology Research at Novartis

Kazia is listed on ASX and NASDAQ, with a market cap of ~AU$ 27 million



As at 31 December 2017

Current Assets*	Debt
~AU$ 14.8 million	Nil

Market Capitalisation	AU$ 27 million
Listing	ASX: KZA NASDAQ: KZIA (1:10 ratio)
Average Daily Volume	ASX: 0.1% /day NASDAQ: 0.2% /day
Average Daily Value	ASX: AU$ 34K /day NASDAQ: AU$ 65K /day
Shares on Issue	48.3 million (35% US, 65% Australia)
Outstanding Options / Warrants	~6 million

* Does not include holding in Noxopharm Limited (ASX: NOX) worth approximately $7.5 million

Our efforts are attracting increasing attention from media and the investment community







THE AUSTRALIAN

CommSec

Lab+Life SCIENTIST www.labonline.com.au

STOCKHEAD

OVARIAN CANCER NEWS TODAY

PharmaDispatch

YAHOO! FINANCE

BiotechDispatch

KAZIA THERAPEUTICS

Two clinical programs, with value-driving inflection points providing impactful newsflow during 2018

GDC-0084

Glioblastoma Multiforme (GBM)

Brain-penetrant PI3K inhibitor, developed to completion of phase I by Genentech

Cantrixil

Ovarian Cancer

Third-generation benzopyran, developed from Australian research with support from Yale University



*MTD = Maximum Tolerated Dose

KAZIA THERAPEUTICS

GDC-0084

Phase II

Glioblastoma Multiforme

Glioblastoma (GBM) is the most common and most aggressive form of primary brain cancer



Glioblastoma Multiforme

133,000 cases per annum worldwide

Indicative Market Opportunity

US$ 1 billion

No clear cause

or strong risk factors

3-4 months

untreated survival

12-15 months

average survival with treatment

Any age, but most common in

60s

Five-year survival

3 – 5%

(breast cancer: 90%)

Most common drug treatment is temozolomide (Temodar®), used after surgery and radiotherapy

Ineffective in approximately two-thirds of patients

KAZIA THERAPEUTICS

Current standard of care is essentially ineffective in up to 65% of GBM cases

Standard of Care ('Stupp Regimen')



Temozolomide is clearly efficacious…



…but only in ~35% of patients with a methylated MGMT promotor



Source: ME Hegi, A-C Diserens, T Gorlia, et al. (2005). *N Engl J Med* 352:997-1003

KAZIA THERAPEUTICS

There is increasing recognition of the need to find treatment options for patients diagnosed with GBM

Growing public attention for brain cancer highlights need for new treatment options

- Senator John McCain's diagnosis in July 2017 highlighted glioblastoma and focused attention on the need for new treatments
- Australian Brain Cancer Mission launched in October 2017, with funding from Cure Brain Cancer Foundation, Federal Government, and Minderoo Foundation



The PI3K pathway is central to many types of cancer, and especially to GBM

PI3K

A central biochemical control mechanism in the growth of cells

PI3K ACTIVATED

TUMOUR GROWTH

85 – 90% of glioblastoma cases have PI3K 'switched on'

>50% of patients at therapeutic doses (45-65mg) in phase I human trials achieved 'stable disease'

PI3K INHIBITED



TUMOUR INHIBITION

GDC-0084 **switches off** PI3K activation, arresting growth of tumour cells

The PI3K class has been validated by approval of a new therapy in September 2017

PI3K class further validated by approval of Bayer's Aliqopa™ (copanlisib) for lymphoma in Sept 2017

- Two PI3K inhibitors now successfully brought to market
  - Zydelig (idelalisib) [Gilead]
  - Aliqopa (copanlisib) [Bayer]
- Neither drug is brain-penetrant, so are unlikely to rival GDC-0084
- Demonstrates that PI3K is a validated pathway to target for effective treatment of cancer
- Both agents approved by US FDA via 'accelerated approval'

GILEAD

BAYER



KAZIA THERAPEUTICS

Genentech's phase I clinical study of GDC-0084 established dosing and showed favourable safety

Safety

- Phase I safety trial conducted by Genentech
- 47 patients enrolled with advanced glioma (grade 3/4); average of three prior lines of therapy
- Most common adverse events were oral mucositis and hyperglycemia (common effects of PI3K inhibitors)
- No evidence of liver, bone marrow, kidney toxicity, or mood disturbances
- Data presented at American Society for Clinical Oncology annual meeting in Chicago, June 2016

Efficacy Signals

	GDC-0084
Arresting Tumour Growth	**40%** Achieved 'stable disease'
Potentially Delaying Progression	**21%** Remained on study for >3 months
Slowing Tumour Metabolism	**26%** Showed 'metabolic partial response' on FDG-PET

DANA-FARBER CANCER INSTITUTE

UCLA University of California, Los Angeles

THE UNIVERSITY OF TEXAS MD Anderson Cancer Center Making Cancer History®

MGH 1811 MASSACHUSETTS GENERAL HOSPITAL

Vall d'Hebron Institut de Recerca

KAZIA THERAPEUTICS

Kazia is about to initiate a phase II clinical trial of GDC-0084 in glioblastoma

Transfer of IND with US FDA from Genentech and updating	✓
Design of phase II clinical study with input from clinicians	✓
Manufacture of drug substance into capsules for clinical trial use	✓
Engagement of contract research organisation (CRO) to conduct study	✓
Meeting with US FDA to discuss study design	✓
Finalisation of clinical trial protocol	✓
Release of study drug	✓
Engagement of clinical trial sites and submission to institutional ethics committees	✓
Commencement of study	Late March / Early April 2018

Other companies focused on the PI3K pathway have been highly-valued in the market

Infinity PHARMACEUTICALS	Single asset company with one PI3K inhibitor in phase I human trials	**US$ 130 million** Market Cap
TG Therapeutics	One PI3K inhibitor in phase II human trials, one other drug in phase III, and two in animal testing	**US$ 1.2 billion** Market Cap
Calistoga Pharmaceuticals	One PI3K inhibitor in phase II human trials	Acquired by big pharma in 2011 for **US$ 375 million**

www.kaziatherapeutics.com

Twitter: @KaziaTx